Sugi Predict

Sugi Predict / Compounds / SCHEMBL2519793

SCHEMBL2519793

SCHEMBL2519793

Cc1cc(Br)c2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 6/20 0.61
▸ CYP2A6 P11509 5/20 0.61
▸ TDP1 Q9NUW8 3/20 0.44
▸ MAOB P27338 1/20 0.44
▸ ALDH1A1 P00352 7/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ CYP1B1 Q16678 1/20 0.41
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 2/20 0.37
▸ TRPM4 Q8TD43 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30640468 1.00 CYP1A2 (0.61) CYP1A2CYP2A6TDP1MAOBALDH1A1
SCHEMBL28995951 0.92 CYP1A2 (0.53) CYP1A2CYP2A6TDP1MAOBALDH1A1
SCHEMBL29524488 0.76 CYP2A6 (0.48) CYP1A2CYP2A6TDP1ALDH1A1HSD17B10
SCHEMBL598829 0.76 CYP1A2 (1.00) CYP1A2CYP2A6TDP1ALDH1A1HSD17B10
SCHEMBL29352143 0.76 CYP1A2 (1.00) CYP1A2CYP2A6TDP1ALDH1A1HSD17B10
SCHEMBL7949503 0.76 CYP2A6 (0.67) CYP1A2CYP2A6TDP1MAOBALDH1A1
SCHEMBL3103031 0.76 CYP2A6 (0.48) CYP1A2CYP2A6TDP1ALDH1A1HSD17B10
SCHEMBL7822962 0.76 CYP1A2 (0.63) CYP1A2CYP2A6TDP1MAOBALDH1A1
SCHEMBL13755384 0.74 CYP1A2 (0.46) CYP1A2CYP2A6TDP1ALDH1A1HSD17B10
Ammonia Solution, Strong SCHEMBL27919233 0.74 CYP1A2 (0.95) CYP1A2CYP2A6TDP1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230365563-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2023-11-16 — — US disclosed
WO-2023214325-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS NOVARTIS AG (CH) 2023-11-09 — — WO disclosed
US-11760744-B2 Fused ring compounds GENENTECH, INC. (US) 2023-09-19 — — US disclosed
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 — — US disclosed
EP-2841429-B1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2020-10-21 — — EP disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
EP-2841433-B1 TETRAZOLINONE COMPOUNDS AND ITS USE SUMITOMO CHEMICAL CO (JP) 2017-06-21 — — EP disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 — — US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 — — US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 — — US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 — — US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 — — US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 — — US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 — — EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 — — EP disclosed
US-4046656-A Photochlorination process for methyl aromatic compounds THE DOW CHEMICAL COMPANY (US) 1977-09-06 — — US disclosed
US-3989746-A ANALGESICS, ANTIINFLAMMATORY AGENTS IKEDA MOHANDO CO., LTD. (JA) 1976-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279025-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS CYP1A2 4527/4885CYP2A6 3249/4885TDP1 3039/4885
US-11760744-B2 Fused ring compounds KRAS, NRAS, HRAS CYP1A2 3503/4885CYP2A6 3939/4885TDP1 4557/4885
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS CYP1A2 4576/4885CYP2A6 3523/4885TDP1 2748/4885
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN CYP1A2 4145/4885CYP2A6 3576/4885TDP1 1239/4885
US-20230365563-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF KRAS, NRAS, BRAF CYP1A2 1599/4885CYP2A6 2066/4885TDP1 2981/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP1A2 4667/4885CYP2A6 3834/4885TDP1 2926/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP1A2 4667/4885CYP2A6 3834/4885TDP1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.